Lisanti Capital Growth LLC bought a new stake in shares of Cardiovascular Systems Inc (NASDAQ:CSII) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 30,750 shares of the medical device company’s stock, valued at approximately $1,204,000. Lisanti Capital Growth LLC owned about 0.09% of Cardiovascular Systems as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in CSII. Partner Fund Management L.P. grew its stake in shares of Cardiovascular Systems by 49.9% during the second quarter. Partner Fund Management L.P. now owns 1,230,921 shares of the medical device company’s stock valued at $39,808,000 after buying an additional 409,767 shares during the last quarter. FMR LLC grew its stake in shares of Cardiovascular Systems by 187.0% during the second quarter. FMR LLC now owns 516,100 shares of the medical device company’s stock valued at $16,690,000 after buying an additional 336,300 shares during the last quarter. Millennium Management LLC grew its stake in shares of Cardiovascular Systems by 2,442.1% during the second quarter. Millennium Management LLC now owns 290,916 shares of the medical device company’s stock valued at $9,408,000 after buying an additional 279,472 shares during the last quarter. BlackRock Inc. grew its stake in shares of Cardiovascular Systems by 9.3% during the second quarter. BlackRock Inc. now owns 2,479,543 shares of the medical device company’s stock valued at $80,188,000 after buying an additional 210,128 shares during the last quarter. Finally, Granahan Investment Management Inc. MA grew its stake in shares of Cardiovascular Systems by 31.8% during the second quarter. Granahan Investment Management Inc. MA now owns 381,056 shares of the medical device company’s stock valued at $12,323,000 after buying an additional 92,042 shares during the last quarter. 79.58% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ CSII opened at $31.09 on Friday. The company has a quick ratio of 4.03, a current ratio of 4.54 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.13 billion, a P/E ratio of 621.80 and a beta of 2.36. Cardiovascular Systems Inc has a 52-week low of $20.58 and a 52-week high of $40.00.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Tuesday, October 30th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The firm had revenue of $56.27 million during the quarter, compared to analysts’ expectations of $55.96 million. Cardiovascular Systems had a net margin of 0.36% and a return on equity of 0.62%. Analysts anticipate that Cardiovascular Systems Inc will post -0.09 EPS for the current year.
A number of research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardiovascular Systems in a research note on Wednesday, October 31st. BidaskClub cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Zacks Investment Research cut Cardiovascular Systems from a “hold” rating to a “strong sell” rating in a research note on Wednesday, September 12th. Stifel Nicolaus assumed coverage on Cardiovascular Systems in a research note on Wednesday, August 22nd. They set a “buy” rating and a $45.00 target price on the stock. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Cardiovascular Systems in a research note on Wednesday, August 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $35.20.
In related news, General Counsel Alexander Rosenstein sold 1,344 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $37.56, for a total value of $50,480.64. Following the completion of the sale, the general counsel now owns 49,469 shares in the company, valued at $1,858,055.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Scott R. Ward purchased 2,500 shares of the stock in a transaction that occurred on Wednesday, August 29th. The stock was purchased at an average price of $38.39 per share, with a total value of $95,975.00. Following the acquisition, the chief executive officer now directly owns 278,362 shares of the company’s stock, valued at approximately $10,686,317.18. The disclosure for this purchase can be found here. Insiders sold 3,177 shares of company stock valued at $119,274 in the last quarter. 2.80% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/11/10/lisanti-capital-growth-llc-invests-1-20-million-in-cardiovascular-systems-inc-csii.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Recommended Story: Initial Public Offering (IPO)
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.